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Type 2 diabetes mellitus (T2Dm) is characterized by defects in both insulin sensitivity and 
glucose-stimulated insulin secretion (GsIs) and is often accompanied by obesity. In this study, 
we show that disruption of thioredoxin binding protein-2 (TBP-2, also called Txnip) in obese 
mice (ob/ob) dramatically improves hyperglycaemia and glucose intolerance, without affecting 
obesity  or  adipocytokine  concentrations.  TBP-2-deficient  ob/ob  mice  exhibited  enhanced 
insulin sensitivity with activated insulin receptor substrate-1/Akt signalling in skeletal muscle 
and GsIs in islets compared with ob/ob mice. The elevation of uncoupling protein-2 (uCP-
2) expression in ob/ob islets was downregulated by TBP-2 deficiency. TBP-2 overexpression 
suppressed glucose-induced adenosine triphosphate production, Ca2 +  influx and GsIs. In β-
cells, TBP-2 enhanced the expression level and transcriptional activity of uCP-2 by recruitment 
of peroxisome proliferator-activated receptor-γ co-activator-1α to the uCP-2 promoter. Thus, 
TBP-2 is a key regulatory molecule of both insulin sensitivity and GsIs in diabetes, raising the 
possibility that inhibition of TBP-2 may be a novel therapeutic approach for T2Dm. 
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R
egulation of glucose homeostasis is critical to life in mammals 
and is largely maintained by pancreatic β-cells, which secrete 
insulin in response to increased concentrations of glucose, 
and is also maintained by the glucose uptake response to insulin in 
peripheral tissues. Obesity disrupts glucose homeostasis and leads 
to diseases such as type 2 diabetes (T2DM), which is characterized 
by aggravated insulin sensitivity and insulin secretion1–5.
Thioredoxin binding protein-2 (TBP-2), also known as thioredoxin 
interacting protein (Txnip)6 and vitamin-D3 upregulated protein-1 
(VDUP1)7, has been identified as a negative regulator of thioredoxin 
and is mainly localized in the nucleus8,9. TBP-2 is a member of the 
α-arrestin protein family, and contains two characteristic arrestin-
like domains and two PPxY sequences, which is a known binding 
motif for WW domain containing proteins10–12. Evidence is growing   
that TBP-2 has an important role in a wide variety of biological   
functions, such as the regulation of cell death, cell growth, cell dif-
ferentiation, immune responses and energy metabolism13–22. As our 
group and others have shown that TBP-2-deficient mice or mice car-
rying the TBP-2 nonsense mutation (HcB-19) have increased insulin 
sensitivity16,20,23 and insulin secretion16,18, we hypothesized that TBP-2 
is involved in defects of insulin sensitivity and secretion in diabetes.
In this study, to address the physiological and molecular role of 
TBP-2 in diabetes, we generated a TBP-2-deficient diabetic mice model 
(ob/ob·TBP-2 − / − ). Remarkably, these mice displayed improved glu-
cose intolerance due to enhanced muscle insulin sensitivity associ-
ated with the insulin receptor substrate-1 (IRS-1)/Akt pathway and 
glucose-stimulated insulin secretion (GSIS) in spite of obesity. The 
augmented insulin secretion was due to the elevation of glucose-
induced adenosine triphosphate (ATP) production with suppression 
of mitochondrial uncoupling protein-2 (UCP-2) expression. UCP-2 is 
known as a negative regulator of GSIS in diabetes24. We showed that 
TBP-2 regulates insulin secretion mainly through UCP-2 transcrip-
tional activation in β-cell lines. We further investigated mechanisms 
for TBP-2 regulation of UCP-2 transcription and analysed interact-
ing proteins for TBP-2 in β-cells. The current results provide a novel 
mechanism for elucidating the pathogenesis of diabetes.
Results
Disruption of TBP-2 in ob/ob mice improves hyperglycaemia. 
Subsequent to a report that TBP-2 expression is elevated in skeletal 
muscle of patients with impaired glucose tolerance or T2DM19, we 
examined the expression levels of TBP-2 mRNA in the tissues of 
leptin-deficient (ob/ob) mice; a genetic animal model of human 
obesity and T2DM. Expression levels of TBP-2 were increased in the 
heart, skeletal muscle, white adipose tissue, kidney and pancreatic 
islets, but were not significantly changed in the liver of ob/ob mice 
compared with wild-type (WT) lean mice (Fig. 1a). To determine 
how TBP-2 is involved in the development of diabetic phenotypes in 
obese mice, we next studied the effect of endogenous TBP-2 in ob/ob 
mice by generating TBP-2-deficient ob/ob mice (ob/ob·TBP-2 − / − ) 
(Fig.  1b).  Ob/ob·TBP-2 − / −   mice  did  not  show  any  significant 
change in food intake, but showed reduced water intake compared 
with that of ob/ob mice (Fig. 1c,d). Surprisingly, although body 
weight was higher in male and as high in female ob/ob·TBP-2 − / −   
mice compared with that in ob/ob mice (Fig. 1e,g), TBP-2 deficiency 
markedly improved hyperglycaemia and urinary glucose excretion 
both  in  male  and  female  ob/ob  mice  (Fig.  1f,h,i).  Furthermore, 
glucose tolerance tests revealed significant amelioration of glucose 
metabolism in ob/ob·TBP-2 − / −  mice (Fig. 1j,k), consistent with 
insulin tolerance tests (ITTs) in which insulin sensitivity significantly 
increased in ob/ob·TBP-2 − / −  mice compared with that in ob/ob 
mice (Fig. 1l,m). These results suggest that disruption of TBP-2 in 
ob/ob mice improves glucose tolerance and insulin sensitivity.
TBP-2 deficiency ameliorates insulin resistance. As altered pro-
duction of adipocytokines accompanied with obesity is implicated 
in insulin resistance and glucose intolerance2,25, body fat composi-
tion, serum monocyte chemotactic protein-1 (MCP-1), adiponectin 
and metabolic parameters of ob/ob·TBP-2 − / −  mice were measured. 
In ob/ob·TBP-2 − / −  mice, body fat and serum levels of fatty acids, 
MCP-1 and lipids increased and serum adiponectin decreased com-
pared with those in WT and/or ob/ob mice (Fig. 2a–i and Supple-
mentary Table S1). TBP-2 deficiency in ob/ob mice did not improve 
adipose size, and TBP-2 − / −  mice showed increased adipose size 
compared with that in WT mice (Fig. 2j). These results show that 
TBP-2 deficiency improves insulin sensitivity without amelioration 
of overeating, obesity and adipocyte dysfunction.
As insulin resistance is derived from defects in insulin signalling 
in peripheral tissues,1 and insulin/Akt signalling regulates many of 
the metabolic actions of insulin1, we investigated phosphorylation 
of Akt in these mice. Akt phosphorylation levels in both basal- and 
insulin-stimulated states were upregulated in skeletal muscle, heart 
and liver of TBP-2 − / −  mice compared with those in WT mice 
(Fig. 2k–p). In addition, TBP-2 deficiency enhanced Akt phospho-
rylation levels in response to insulin in mouse embryonic fibrob-
lasts (MEFs) (Fig. 2q,r), suggesting that TBP-2 deficiency enhances 
insulin/Akt signalling. Although ob/ob mice showed suppression 
of Akt phosphorylation in response to insulin in skeletal muscle, 
heart and liver, compared with those in WT mice without affect-
ing the concentration of total Akt protein, TBP-2 deficiency in 
ob/ob mice restored the suppression of Akt phosphorylation in skel-
etal muscle and heart, but not liver (Fig. 2k–p). The phosphorylation 
of FoxO1, an Akt downstream signalling molecule, was also not 
enhanced in the liver of ob/ob·TBP-2 − / −  mice. Severe lipid accu-
mulation occurred in the liver both in ob/ob and ob/ob·TBP-2 − / −   
mice (Supplementary Fig. S1a,b). Thus, the amelioration of insulin 
sensitivity by TBP-2 deficiency in ob/ob mice seems to be due to 
activation of insulin/Akt signalling in skeletal muscle.
TBP-2 deficiency enhances IRS-1 expression in skeletal muscle. 
We performed microarray analyses (data deposited in GEO, acces-
sion number GSE24851) of the skeletal muscle in WT, TBP-2 − / − , 
ob/ob, ob/ob·TBP-2 − / −  mice to investigate how TBP-2 regulates 
Akt signalling and insulin sensitivity. We found that several insulin 
signalling-related genes, such as Igf1, Igf2bp2, Igfbp4, Irs-1(IRS-1), 
Pik3r1 and Pik3r5, were upregulated by TBP-2 deficiency both in 
WT and ob/ob background mice (Supplementary Table S2). The 
upregulation  was  confirmed  by  real-time  reverse  transcription 
(RT)–PCR analyses (Fig. 3a). IRS-1 gene expression was down-
regulated  in  skeletal  muscle  of  ob/ob  mice  (Fig.  3a)  or  T2DM 
patients26. We focused on IRS-1, as IRS-1 is one of the key mol-
ecules for insulin signalling and is an upstream molecule of Akt 
in skeletal muscle27. IRS-1 protein levels were downregulated in 
ob/ob mice, whereas IRS-1 protein levels and phosphorylation of 
Akt were upregulated by TBP-2 deficiency in skeletal muscle of 
WT and ob/ob background mice (Fig. 3b). Thus, TBP-2 regulates 
the expression of molecules involved in insulin signalling, which 
may enhance insulin sensitivity in skeletal muscle. Gene expres-
sions of peroxisome proliferator-activated receptor (PPAR) signal-
ling were also enhanced by TBP-2 deficiency in skeletal muscle 
(Supplementary Fig.S2).
TBP-2  deficiency  improved  impairment  of  insulin  secretion. 
TBP-2 − / −  mice and HcB-19 mice show enhanced insulin secre-
tion in vivo16,18. Although obesity usually leads to insulin resistance, 
only a subset of obese- and insulin-resistant individuals progress 
to T2DM. In ob/ob mice and humans, the determinant factor for 
declining glucose tolerance is a progressive decrease in GSIS3. Of 
note, ob/ob mice showed elevated blood glucose with an increase in 
body weight after ages 5 or 6 weeks, whereas TBP-2-deficient ob/ob 
mice did not show elevation of blood glucose, in spite of similar 
increases in body weight. In addition, although blood glucose levels ARTICLE     
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were lower in ob/ob·TBP-2 − / −  mice, compared with those in ob/ob 
mice, serum insulin levels in ob/ob·TBP-2 − / −  mice were as high 
as those in ob/ob mice at ages 11 and 14 weeks in both males and 
females (Fig. 4a,b). Although we observed no significant change in 
islet mass between ob/ob·TBP-2 − / −  mice and ob/ob mice, as well as 
between TBP-2 − / −  and WT mice (Fig. 4c,d), serum insulin levels 
after glucose loads in vivo were enhanced in ob/ob·TBP-2 − / −  mice 
compared with those in ob/ob mice (Fig. 4e). To evaluate the effect of 
TBP-2 deficiency on insulin secretion ex vivo, pancreatic islets were 
isolated from WT, TBP-2 − / − , ob/ob and ob/ob·TBP-2 − / −  mice. 
TBP-2 deficiency enhanced GSIS in both WT and ob/ob mice (Fig. 
4f,g). Insulin secretion from ob/ob islets in response to high glucose 
was blunted, and was improved by TBP-2 deficiency (Fig. 4g,h). These 
results suggest that TBP-2 deficiency improves impairment of GSIS 
from islets, which contributes to improvement of glucose intolerance 
in ob/ob mice. As glucose metabolism generates ATP as a signal to 
enhance insulin secretion28, we further determined ATP content of 
islets in these mice. Under a high (16.7 mM) glucose condition, TBP-
2 deficiency enhanced ATP content in both WT and ob/ob islets (Fig. 
4i,j). WT islets showed a significant increase in ATP production with 
increased glucose concentrations (Fig. 4i). In ob/ob islets, increases 
in ATP content with increasing glucose levels were not as marked 
(Fig. 4j,k), as in TBP-2 deficiency where the ratio of ATP content 
at high glucose (16.7 mM) relative to basal glucose (2.8 mM) was 
significantly increased (Fig. 4k). Regulation of mitochondrial ATP 
production has a central role in insulin secretion from pancreatic β-
cells4, and the reduction of mitochondrial ATP production parallels 
abnormal mitochondrial structure, including swelling and alteration 
in volume density and cristae structure29, which is often observed 
in diabetes5,30. We then studied the morphology of mitochondria in 
WT, TBP-2 − / − , ob/ob and ob/ob·TBP-2 − / −  β-cells using electron 
microscopy. Morphological apoptotic processes, including conden-
sation of chromatin around the nuclear membrane and swelling of 
the cytoplasm and a decrease in the number of insulin granules in 
β-cells, were not observed in ob/ob and ob/ob·TBP-2 − / −  mice at 
10 weeks ages (Supplementary Fig. S3a,b). However, the abnormal 
mitochondrial morphological changes, such as swelling associated 
with an increased number of disarrayed or disappeared cristae and a 
reduced electron density of the matrix, were observed in ob/ob mice, 
whereas the abnormalities were improved in ob/ob·TBP-2 − / −  mice 
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Figure 1 | Disruption of TBP-2 in ob/ob mice improves hyperglycaemia and glucose intolerance without affecting obesity. (a) Quantitative RT–PCR of 
TBP-2 expression in the heart, skeletal muscle, white adipose, liver, pancreatic islet and kidney of WT (open bar, lean, n = 3) and ob/ob mice (closed bar, 
n = 3). (b) Generation of the ob/ob·TBP-2 − / −  mice. male food intake (c), male water intake (d), male body weight (e), male blood glucose in fed ad lib (f),  
female body weight (g), female blood glucose in fed ad lib (h) were assessed, N ≥ 6. WT, grey rectangles; TBP-2 − / − , white rectangles; ob/ob, black circles;  
ob/ob·TBP-2 − / − , red circles. (i) urine glucose (mg per 100 ml) of males and females. WT (grey bar; n = 11), ob/ob (black bar; n = 9), ob/ob·TBP-2 − / −  
(red bar; n = 11). (j, k) Intraperitoneal glucose tolerance test (IPGTT). Following an overnight fast, mice were injected with 0.5 g kg − 1 glucose, IP (time 0). 
Blood glucose values (j) and area under the curve (AuC) levels (k) were assessed before and at 15, 30, 60 and 120 min into the IPGTT. ob/ob (black 
circle, n = 5), ob/ob·TBP-2 − / −  (white circle, n = 6). (l, m) IP insulin tolerance test (IPITT). Following a 6 h fast, mice were injected with 1 u/kg of insulin, 
i.p. (time 0). Blood glucose value (l) and AuC levels (m) were assessed before and at 15, 30, 60 and 90 min into the IPITT. ob/ob (black circle, n = 5), 
ob/ob·TBP-2 − / −  (white circle, n = 6). Data are presented as mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001, versus control (t-test).ARTICLE
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(Fig. 4l). These results showed that mitochondrial morphological 
changes and metabolic dysfunctions in β-cells are improved by TBP-
2 deficiency in ob/ob mice.
TBP-2 suppresses mitochondrial ATP production and GSIS. To 
delineate how TBP-2 deficiency protects against the impaired GSIS 
in ob/ob islets, we next examined the dose effect of TBP-2 on GSIS 
in the rat β-cell line INS-1 cells. Silencing of TBP-2 (RNAi1 and 
RNAi2) enhanced GSIS in INS-1 cells (Fig. 5a,b,d). On the contrary, 
transient TBP-2 overexpression suppressed GSIS (Fig. 5c,e). Induc-
tion of TBP-2 in cloned INS-1 cells, where TBP-2 expression was 
doxycycline-off dependent, suppressed GSIS, but not KCl-induced   
insulin secretion (Fig. 5f,g). TBP-2 induction did not cause a sig-
nificant  change  in  ATP  levels  at  low  (2.8 mM)  glucose  level,  but 
it suppressed ATP levels at high (16.7 mM) glucose in INS-1 cells   
(Fig. 5h). Furthermore, glucose-induced intracellular Ca2 +  elevation,   
which is the eventual trigger for the exocytosis of insulin granules, 
was significantly decreased in TBP-2-induced INS-1 cells (Fig. 5i). We 
then analysed mitochondrial membrane potentials (∆ψm) in TBP-2-
induced INS-1 cells. We showed that ∆ψm was significantly reduced 
in TBP-2-induced INS-1 cells cultured with low (3 mM) and high 
(20 mM) glucose (Fig. 5j) and with 11 mM glucose for 24 h (Fig. 5k) 
using  a  flowcytometer  and  fluorescence  microscopy,  respectively. 
Cellular ATP is mainly produced by glycolysis and mitochondrial 
metabolism. In pancreatic β-cells, glycolytic flux regulates glucose 
metabolism, which has an important role in insulin secretion, and 
glucokinase is a pace-setting enzyme in glycolysis31. Therefore, effects 
of TBP-2 on glucokinase activity were examined. Glucokinase activity   
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mCP-1 (h) were measured in 15 weeks aged mice, N ≥ 7. (i) Blood adiponectin concentration was measured in 6, 10 and 15 weeks aged mice, n =  ≥ 5. (j) 
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of pAkt/Akt ratios in skeletal muscle (n), heart (o) and liver (p). open and closed bar represents without or with insulin stimulation, respectively. (q) Loss  
of endogenous TBP-2 mRnA in mEFs. (r) IB analyses. TBP-2 deficiency enhances insulin/Akt signalling in primary mEFs. mEFs were serum starved for 12 h  
and then stimulated with insulin (100 nm) for different times. Data are presented as mean ± s.d. *P <  0.05, **P <  0.01, versus control (t-test).ARTICLE     
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was not affected by dox-off-dependent TBP-2 induction in β-cells 
(Fig. 5l). Furthermore, effects of TBP-2 on insulin secretion stimu-
lated by fuel secretagogues, which bypass glycolysis and are metabo-
lized in mitochondria to generate ATP, were determined using meth-
ods previously described32. Insulin secretion induced by pyruvate and 
α-ketoisocaprotate plus monomethyl succinate was also suppressed 
by TBP-2 overexpression in β-cells (Fig. 5m). These results indicate 
that impaired GSIS by TBP-2 induction is attributable to reduction in 
mitochondrial metabolism, but not to a decrease in glycolysis.
TBP-2  has  been  reported  to  enhance  apoptosis  in  pancreatic   
β-cells and other cells21. TBP-2 induction did not increase apoptosis in 
48 h, but apoptosis was slightly increased on 72 h after high (20 mM) 
glucose treatment (Fig. 5n). β-Cell apoptosis was not changed sig-
nificantly between ob/ob and ob/ob TBP-2 − / −  mice generated in a 
C57BL/6J background at 10 weeks of age (Supplementary Figs S3a,b 
and S4a), whereas TBP-2 deficiency suppressed β-cell apoptosis at 
age 36 weeks in C57BL/6J background mice (Supplementary Fig. 
S4b,c).These results suggest that TBP-2 negatively regulates GSIS by 
suppressing glucose-induced mitochondrial ATP production in INS-
1 cells and islets before causing apoptosis. Treatment with reactive 
oxygen species scavengers (vitamins C + E) scarcely recovered the 
insulin secretion suppressed by TBP-2 overexpression in INS-1 cells 
(Supplementary Fig. S5), suggesting that mitochondrial dysfunction 
caused by TBP-2 is not mainly attributed to an increase in reactive 
oxygen species by reducing the scavenger effect of thioredoxin.
TBP-2 enhances UCP-2 transcriptional activity. Impairment in 
mitochondria  ATP  production  often  occurs  with  uncoupling24. 
Mitochondrial UCP-2 is a key regulator of ATP production and 
insulin secretion in pancreatic β-cells, and UCP-2 deficiency has 
been shown to improve GSIS and glucose-induced ATP production 
in ob/ob mice24. Thus, we measured UCP-2 mRNA in TBP-2-over-
expressed INS-1 cells. Strikingly, there was a significant increase in 
UCP-2 mRNA levels in the TBP-2-induced cells (Fig. 6a). Further-
more, TBP-2 induction also increased UCP-2 protein levels in the 
mitochondria of INS-1 cells (Fig. 6b). UCP-2 expression is known to 
be upregulated by the increase in activity of transcriptional co-activa-
tors; e.g., PPARγ co-activator-1α (PGC-1α)33. TBP-2 is also induced 
by PGC-1α overexpression in INS-1 cells (Fig. 6c). We examined the 
effect of TBP-2 overexpression on activity of UCP-2 -86 promoter, 
containing Sp1, SRE and double E-box elements, the essential ele-
ments for a response to fatty acids and PGC-1α33,34. TBP-2 enhanced 
UCP-2 transcriptional activity through this -86 promoter region 
and the PGC-1α-induced activation was also augmented by TBP-2 
expression (Fig. 6d), suggesting that TBP-2 enhances UCP-2 tran-
scriptional activity and expression in INS-1 cells. To investigate how 
TBP-2 regulates UCP-2 transcriptional activity, we tested whether 
TBP-2  affects  PGC-1α  protein  levels.  Dox-off-dependent  TBP-2 
overexpression  did  not  change  PGC-1α  protein  levels  (Supple-
mentary Fig. S6). Next, we used chromatin immunoprecipitations 
(ChIPs) to investigate whether TBP-2 expression influences PGC-1α  
binding efficiency to the UCP-2 promoter region. Sheared chromatin   
was collected from INS-1 cells treated with or without doxycycline, 
and  then  immunoprecipitated  with  anti-RNA  polymerase  II  or 
control-mouse immunoglobulin G or anti-PGC-1α antibody. PCR 
was performed with primers flanking the SP1, SRE and E-boxes 
region of UCP-2 (UCP-2 -86). PGC-1α was recruited to the UCP-2 
-86 promoter region and dox-off-dependent TBP-2 overexpression 
enhanced PGC-1α binding efficiency to the region (Fig. 6e,f). These 
results indicate that TBP-2 facilitates PGC-1α recruitment in the 
UCP-2 promoter region, enhancing UCP-2 transcriptional activity 
in INS-1 cells. Next, we tested whether TBP-2-dependent UCP-2 
expression is critical for aggravated GSIS using UCP-2 knockdown 
in  dox-off-dependent  TBP-2-overexpressing  INS-1  cells.  UCP-2   
knockdown reversed suppression of GSIS by TBP-2 induction (Fig. 6g   
and Supplementary Fig. S7), suggesting that TBP-2-induced sup-
pression  of  GSIS  is  mainly  through  UCP-2  expression.  Further-
more, the expression level of UCP-2 mRNA was enhanced in islets 
of ob/ob mice, whereas TBP-2 deficiency dramatically reduced it in 
ob/ob islets (Fig 6h). Mitochondrial mass, determined as mitochon-
drial coding gene (mtDNA)/nuclear coding gene (COX I) expres-
sion ratio in pancreatic islets, was not affected by TBP-2 deficiency 
(Fig. 6i). Next, we examined the effect of the mitochondrial uncou-
pler carbonyl cyanide m-chlorophenyl-hydrazone (cccp) on GSIS 
in Tet-TBP-2 INS-1 cells with or without doxycycline and in TBP-2 
deficient ob/ob islets. Uncoupling by cccp decreased the GSIS at the 
concentration 25–1,000 nM (Supplementary Fig. S8a). This result 
suggests that mitochondria metabolism is responsible for GSIS in 
β-cells and is tightly regulated by uncoupling. In dox-off tet-TBP-2 
INS-1 cells, TBP-2 overexpression suppressed the GSIS equivalent 
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to the level elicited by 25 nM cccp (Supplementary Fig. S8b). More 
importantly, cccp had a larger effect on GSIS and glucose-induced 
ATP  production  in  TBP-2-deficient  ob/ob  islets  compared  with 
ob/ob islets (Fig. 6j,k). These results suggest that TBP-2-depend-
ent regulation of GSIS is mainly achieved through mitochondrial 
uncoupling and metabolism.
These results suggest that TBP-2 does not affect mitochondrial 
biogenesis but enhances UCP-2 transcriptional activity through the 
PGC-1α-dependent pathway, and the induction of the TBP-2-UCP-
2 axis causes the defect of GSIS in ob/ob mice.
Mybbp1a is a novel candidate binding protein for TBP-2. To 
obtain  further  insight  on  how  TBP-2  regulates  gene  expression 
in β-cells, we purified the TBP-2 protein complex using tosyl (p-
toluene sulfonyl)-activated magnetic beads (Ts beads). His-tagged-
TBP-2 protein was conjugated to the beads and incubated with 
nuclear extract of INS-1 cells. After washing, the eluate fractions 
were  subjected  to  SDS  gel  electrophoresis  and  silver  staining   
(Fig. 7a). The specific bands on silver staining were subjected to 
proteolytic  digestion  and  mass  spectrometry.  Mybbp1a  (p160), 
Mybbp1a (p140), GCN and NonO/p54nrb homologue were iden-
tified (Fig. 7b and Supplementary Table S3). Intriguingly, Mybbp1a 
is reported to inhibit PGC-1α function and transcription of PGC-
1α target genes35. Therefore, we examined the interaction between 
TBP-2 and Mybbp1a. We showed that Mybbp1a is detected in 
elution  samples  from  TBP-2  protein  beads  by  anti-Mybbp1a 
antibody (Fig. 7c). To determine whether TBP-2 and Mybbp1a 
interact directly in vivo, we performed co-immunoprecipitation 
using FLAG-HA-tagged Mybbp1a and Myc-tagged TBP-2 expres-
sion vectors. Myc-tagged TBP-2 was co-immunoprecipitated with 
FLAG-HA-tagged  Mybbp1a  in  HEK293  cells  (Fig.  7d).  Finally, 
we examined whether Mybbp1a regulates UCP-2 transcriptional 
activity. Mybbp1a suppressed PGC-1α-dependent UCP-2 trans-
criptional  activity  and  the  suppression  was  reversed  by  TBP-2 
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co-expression (Fig. 7e). These results provide a model that TBP-2 
suppresses Mybbp1a function possibly through protein–protein 
interaction, leading to the activation of PGC-1α-dependent UCP-
2 transcription (Fig. 7f).
Discussion
In this study, we demonstrated that disruption of TBP-2 expression 
augments both insulin sensitivity and secretion, resulting in the 
amelioration of glucose intolerance in a diabetic mice model where 
TBP-2 expression is increased. The mechanism by which TBP-2 is 
increased in several tissues and pancreatic islets of ob/ob mice is 
presently unknown. It is possible that high blood glucose or obese-
induced  adipocytokines  enhance  TBP-2  expression,  as  TBP-2  is 
upregulated by several stimulations and stresses36,37. Several reports 
have  shown  that  TBP-2  expression  is  regulated  by  mitochon-
drial metabolism and glycolysis through the transcription factor   
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MondoA38–41. These reports indicate that TBP-2 expression is tightly 
regulated in response to changes in energy status.
TBP-2 deficiency in ob/ob mice improved hyperglycaemia, glucose 
intolerance and insulin resistance without amelioration of obesity   
(Fig. 1e–m). A previous study showed that HcB-19 mice crossed 
with ob/ob mice improved glucose tolerance21. Other studies showed 
that silencing of TBP-2 expression enhanced glucose uptake in adipo-
cytes and human skeletal myocytes, whereas TBP-2 overexpression   
R
e
l
a
t
i
v
e
 
m
R
N
A
/
β
-
a
c
t
i
n 4
2
3
1
0
***
dox (+) dox (–)
dox(+) dox(–)
Palmitate
UCP-2
Porin
0 24 48 72 0 24 48 72 h
kDa
33
31
UCP-2 promoter
SP1
–86 0
Luciferase SRE E-Boxes
TBP-2
Control PGC-1α kDa
75
37
50
β-Actin
PGC-1α
14
12
10
8
6
4
2
0
R
e
l
a
t
i
v
e
 
a
m
o
u
n
t
 
o
f
U
C
P
-
2
/
P
o
r
i
n
*
* *
*
dox (+) dox (–)
0 24 48 72 0 244872 h
PGL4.10 UCP-2   –86 PGL4.10
***
**
L
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
(
f
o
l
d
)
TBP-2
PGC-1α
6
5
4
3
2
1
0
– – + +
– – + +
– – + +
– – + +
UCP-2 β-Actin
dox (+) (–) (+) (–)
RNA Pol II
IgG
PGC-1�
Input (1%)
bp
300
200
300
200
300
200
200
300
C
h
l
P
 
(
%
 
o
f
 
i
n
p
u
t
)
0.8
0.6
0.2
0
0.4
dox
*
*
– + – + – +
RNA
Pol II IgG
PGC-1�
dox
NC
UCP-2 si 1
UCP-2 si 2
H TBP-2
R UCP-2
R β-Actin
+ + + – – –
+ – – – – +
– – – – + +
– – – – + +
bp
400
300
200
100
200
I
n
s
u
l
i
n
 
s
e
c
r
e
t
i
o
n
 
(
r
a
t
i
o
)
5
4
3
2
1
0
*
*
*
dox
20 mM
glucose
+ + – –
+ + – – + + – –
+ + – –
+ + – –
+ + – –
NC UCP-2 si 1 UCP-2 si 2
R
e
l
a
t
i
v
e
 
m
R
N
A
/
β
-
a
c
t
i
n
2.0
1.0
1.5
0.5
0
7
6
5
4
3
2
1
0
M
i
t
o
c
h
o
n
d
r
i
a
l
/
n
u
c
l
e
a
r
 
D
N
A
(
C
O
X
1
/
c
y
c
l
o
p
h
i
l
i
n
)
* ***
WT
TBP-2–/–
ob/ob
ob/ob
TBP-2–/–
WT
TBP-2–/–
ob/ob
ob/ob
TBP-2–/–
I
n
s
u
l
i
n
 
s
e
c
r
e
t
i
o
n
 
(
n
g
 
p
e
r
 
i
s
l
e
t
 
p
e
r
 
3
0
 
m
i
n
)
4
3
2
1
0
Glucose 3 20
ob/ob ob/ob TBP-2–/–
3 20 mM
cccp (nM) 0 0 25 200 1,000 0 25 200 1,000 0 0 0 25 200 1,000 0 25 200 1,000 0
Glucose 3 20
ob/ob ob/ob TBP-2–/–
3 20 mM
cccp (nM)
*** *** ***
***
***
**
** **
** NS
*
***
*** ***
**
** NS
NS
A
T
P
 
(
p
m
o
l
 
p
e
r
 
i
s
l
e
t
 
p
e
r
 
3
0
 
m
i
n
) 100
80
60
40
20
0
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precipitated in the presence of control-mouse IgG, anti-RnA polymerase II (RnA pol II) or anti-PGC-1α antibody. Primers for PCR are rat UCP-2 promoter 
region primers and rat β-actin primers. (f) qRT–PCR analyses for ChIP were performed. (g) Insulin secretion in dox-off-dependent TBP-2 overexpressing 
Ins-1 cells with or without dox and knockdown of uCP-2 (si1 and si2). The left panel shows RT–PCR analysis of human TBP-2 expression (H TBP-2) to 
confirm the effect of dox, rat UCP-2 expression (R uCP-2) to confirm the knockdown effect, and rat β-actin (R β-actin). (h) qRT–PCR analyses of uCP-2 
mRnA in isolated pancreatic islets of WT, TBP-2 − / − , ob/ob and ob/ob·TBP-2 − / −  mice. (i) qRT–PCR was used to determine mitochondria content by 
measuring the expression of mitochondrial gene (CoX I)/nuclear gene (cyclophilin) ratios. (j, k) Effect of cccp treatment for 30 min on insulin secretion 
(j, ng per islet per 30 min) and ATP levels (k, pmol per islet per 30 min) in ob/ob and ob/ob TBP-2 − / −  islets. Data are presented as mean ± s.d. *P < 0.05, 
**P < 0.01, ***P < 0.001, versus control (t-test). ARTICLE     
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inhibited  glucose  uptake19.  Entire  or  muscle-specific  TBP-2 − / −   
mice showed enhanced glucose uptake in the skeletal muscle and   
adipose  with  a  high-fat  diet23,42.  The  current  study  is  consistent 
with these previous reports. The restoration of glucose tolerance in   
ob/ob·TBP-2 − / −  mice could not be explained by changes in energy 
balance or hormonal level of adipocytokines, such as adiponectin, free 
fatty acids and MCP-1. Insulin resistance in skeletal muscle and liver 
is mainly caused by inactivation of insulin/Akt signalling1. We showed 
that TBP-2 deficiency in ob/ob mice improved Akt signalling in muscle 
but not liver (Fig. 2k–p). Moreover, IRS-1 gene and several insulin sig-
nalling genes were upregulated in skeletal muscle by TBP-2 deficiency 
both in WT and ob/ob mice (Fig. 3a and Supplementary Table S2).   
IRS-1 protein levels were downregulated in the skeletal muscle of 
ob/ob mice compared with that of WT mice, while IRS-1 protein 
levels were also upregulated by TBP-2 deficiency in both WT and 
ob/ob mice (Fig. 3b). As IRS-1 has a pivotal role in insulin sensitivity 
in muscle27, TBP-2 regulates insulin signalling possibly through the 
regulation of IRS-1 gene expression in muscle. Interestingly, TBP-2 
deficiency did not change IRS-2 gene expression, which is known as a 
main regulator of liver insulin sensitivity43 in skeletal muscle (Fig. 3a).   
These results suggest that TBP-2 regulates IRS-1-related insulin sen-
sitivity in skeletal muscle, but not IRS-2-related insulin sensitivity in 
liver. The molecular mechanism of how TBP-2 regulates the expres-
sion of IRS-1 and insulin signalling genes in skeletal muscle is now 
under investigation. We also found that gene expression of PPARs 
and their target genes, such as PPARγ, PPARα, Acaca, Fabp3, Scd1 and 
Pdk4, are enhanced by TBP-2 deficiency in skeletal muscle (Supple-
mentary Fig. S2), similar to previous reports in the liver and adipose 
tissue of TBP-2 − / −  mice16,42. As PPAR signalling augments insulin 
sensitivity44, it may also be involved in enhanced insulin sensitivity by 
TBP-2 deficiency.
The GSIS was significantly impaired in ob/ob islets, whereas insu-
lin secretion from ob/ob·TBP-2 − / −  islets was restored in vivo and 
ex vivo, suggesting that the ablation of TBP-2 in pancreatic islets of 
ob/ob mice augments GSIS. Our results indicate that upregulation 
of TBP-2 suppresses GSIS by reducing ATP production in pancre-
atic β-cells. Meanwhile, glycolytic activity was not changed by TBP-2 
overexpression (Fig. 5l) in β-cell lines. Recently, several groups have 
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shown that TBP-2 regulates β-cell mass and β-cell apoptosis in C3H/
He background mice and INS-1 cells21,22,45,46. Our results also support 
these previous studies. TBP-2 deficiency suppressed β-cell apopto-
sis at age 36 weeks in C57BL/6J background mice (Supplementary 
Fig. S4b,c). In contrast, while β-cell apoptosis was not changed sig-
nificantly between ob/ob and ob/ob·TBP-2 − / −  mice generated in 
C57BL/6J background mice at 10 weeks age (Supplementary Figs 
S3a,b and S4a,c), TBP-2 deficiency improved GSIS in ob/ob mice at 
age 10–14 weeks. Taken together, improvement of GSIS by TBP-2 
depletion in vivo was attributable to functional amelioration of β-
cells but not to an increase in β-cell mass, at least, in mice of this age. 
Moreover, impaired GSIS without reduction in β-cell mass preceded 
significant  detection  of  apoptosis  in  islets  in  ob/ob  mice,  which 
supports the pathogenic importance of functional impairment of   
β-cells. Thus, TBP-2 seems to regulate not only β-cell apoptosis but also   
β-cell energy metabolism in the diabetic condition.
Impairment of GSIS in ob/ob mice was improved by TBP-2 defi-
ciency. This phenotype resembles ob/ob mice lacking UCP-2, which 
is a negative regulator of GSIS24. We showed that TBP-2 deficiency 
cancelled upregulation of UCP-2 gene expression in ob/ob islets 
(Fig. 6h). Therefore, UCP-2 regulation by TBP-2 seems to be impor-
tant in the development of the diabetic phenotype in ob/ob mice. 
UCP-2 knockdown recovered the TBP-2-dependent impairment in 
GSIS (Fig 6g). Furthermore, the mitochondrial uncoupling reagent 
cccp had a greater effect on GSIS and glucose-induced ATP produc-
tion in TBP-2-deficient ob/ob islets compared with those in ob/ob 
islets (Fig. 6j,k). These results suggest that TBP-2-dependent regu-
lation of GSIS is mainly due to mitochondrial uncoupling derived 
from UCP-2 expression.
The results from a ChIP assay indicated that TBP-2 regulates 
UCP-2 expression by facilitating PGC-1α recruitment to the UCP-
2 promoter region. Furthermore, we identified Mybbp1a as a novel 
binding protein of TBP-2. Mybbp1a is reported to inhibit PGC-
1α function and transcription of PGC-1α target genes through 
direct  protein–protein  interaction35.  Indeed,  Mybbp1a  overex-
pression  suppressed  PGC-1α-dependent  UCP-2  transcriptional 
activity (Fig. 7e), and TBP-2 overexpression hampered the effect of 
Mybbp1a on PGC-1α-dependent UCP-2 promoter activity in INS-
1 cells (Fig. 7e). These results suggest a model that TBP-2 regulates 
UCP-2 expression through Mybbp1a and PGC-1α pathway (Fig. 
7f). Recently, it has been reported that α-arrestin family proteins 
are considered to act as adaptor protein for the E3-ubiquitin ligases 
in the yeast system47 and TBP-2 interacts with WW domain of 
HECT domain containing E3-ubiquitin ligases through the PPxY 
motif of TBP-212. These reports provide a hypothesis that TBP-2 
negatively regulates Mybbp1a by protein degradation through E3-
ubiquitin ligases. This possibility should be further investigated.
In this study, we demonstrated that ablation of TBP-2 expression 
augments both insulin sensitivities by enhancing IRS-1/Akt signal-
ling in skeletal muscle and GSIS by suppressing UCP-2 transcrip-
tion and maintaining mitochondrial function in pancreatic β-cells,   
resulting  in  the  amelioration  of  glucose  intolerance  and  hyper-
glycaemia. The proposed mechanism for this effect is summarized 
in Figure 8 and Supplementary Figure S9. These findings raise the 
possibility that the inhibition of either TBP-2 activity or expression 
may be a novel therapeutic approach for type 2 diabetes.
Methods
Animal experiments. TBP-2-knockout mice were generated as described previ-
ously17. Mice were backcrossed for at least 11 generations with a C57B/6 genetic 
background. Animals were maintained in a specific pathogen-free animal facility 
on a 12-h light–dark cycle at an ambient temperature of 21 °C. They were given free 
access to water and food.
Age- and sex-matched mice were used for all animal experiments. All proce-
dures involving animals were performed in accordance with protocols approved 
by the Animal Care and Research Advisory Committee of the Institute for Virus 
Research at Kyoto University.
Generation of TBP-2-deficient ob/ob mice. C57BL6 ob/ +  were purchased from 
the Jackson Laboratory. To generate ob/ob·TBP-2 − / −  mice, TBP-2 − / −  mice were  
crossed with ob/ +  mice creating compound heterozygotes, ob/OB·TBP-2 + / − .  
In the second cross, compound heterozygotes were crossed to generate the following  
animals of which both males and females were collected and studied further: WT 
mice ( + / +  at both ob and TBP-2 loci), ob/ob mice (ob/ob at the ob locus and  + / +  
at the TBP-2 locus), TBP-2 − / −  mice ( + / +  at the ob locus and  − / −  at the TBP-2 
locus) and ob/ob·TBP-2 − / −  mice (ob/ob at the ob locus and  − / −  at the TBP-2 
locus). The ob allele was genotyped as previously described48.
Intraperitoneal glucose or ITTs. For the intraperitoneal (IP) glucose tolerance 
test, following an overnight fast, ob/ob and ob/ob·TBP-2 − / −  mice were injected 
with 0.5 g kg − 1 or 1 g kg − 1 glucose. Blood glucose values were assessed before and at 
15, 30, 60 and 120 min after the IP administration of glucose using glucose PILOT. 
Serum insulin values were assessed before and at 5, 15, 30 and 45 min after the IP 
administration of glucose using an Insulin ELISA kit. For the IP ITTs, mice were 
fasted for 6 h and then injected with 1 U kg − 1 insulin.
Cell culture and transfection. INS-1 cells were cultured at 37 °C with 5% CO2 
in air in RPMI1640 (Sigma-Aldrich), supplemented with 10% (v/v) fetal bovine 
serum, 1% (v/v) penicillin/streptomycin antibiotics, 10 mM HEPES, 2 mM l-
glutamine, 1 mM sodium pyruvate and 50 µM β-mercaptoethanol (RPMI for INS-1 
medium). INS-1 cells were transfected with TBP-2 small interfering RNA (siRNA) 
or negative control siRNA (Qiagen) for 72 h or with pCMV-Tag2B-TBP-2 or 
control pCMV-Tag2B (Stratagene) plasmid for 24 h and cultured with RPMI1640 
for INS-1 medium.
Isolated pancreatic islet studies. Pancreatic islets were isolated from mice ac-
cording to a method used for rats49.
Generation of INS-1 cells with inducible TBP-2 expression. Stable INS-1 cells, 
which carry the reverse tetracycline/doxycycline-dependent transactivator pTRE2 
(pTet-Off, Clontech), were prepared. After selection with 500 µg ml − 1 G418, resist-
ant colonies were isolated with limiting dilution methods in 96-well plates. One 
clonal line that exhibited very high tetracycline-off-inducible luciferase activity and 
undetectable basal luciferase activity was chosen and used for a second round of 
transfection with the TBP-2 expression plasmid (pTRE2 pur-TBP-2-FLAG). After 
selection with 500 ng ml − 1 puromycin and doxycycline-off-induced TBP-2 expres-
sion, clones were isolated.
Insulin secretion assay using INS-1 cells. INS-1 cells were transfected with TBP-
2 siRNA (Rn_Txnip_1 and 5) or UCP-2 siRNA (Rn_UCP-2_5 and 6) or negative 
control siRNA (purchased from Qiagen) for 72 h, or with pCMV-Tag2A-TBP-2 or 
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Figure 8 | A model for metabolic function of TBP-2 in diabetes. Role of 
TBP-2 in promoting obesity-induced type 2 diabetes. Environmental stresses 
including obesity cause upregulation of TBP-2. sustained expression of 
TBP-2 may impair mitochondrial function and insulin secretion in β-cells 
and aggravate insulin resistance in skeletal muscle. Augmented expression 
of TBP-2 may also result in β-cell apoptosis. These changes lead to glucose 
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control pCMV-Tag2A (Stratagene) plasmid for 24 h. Then, the cells were cultured 
in Krebs Ringer bicarbonate buffer (KRBB) (as mentioned below) or RPMI1640 
for INS-1 medium with 2.8 mM (5 mM) or 16.7 mM (20 mM) glucose containing 
RPMI medium and the supernatant was collected 30 min after the addition of glu-
cose. Insulin concentration was measured by an Insulin ELISA kit. Similar analyses 
were performed in Tet-TBP-2 INS-1 cells pretreated with or without doxycycline 
for 24 to 48 h. One mM pyruvate (sodium pyruvate, Nacalai Tesque) or 3 mM  
α-ketoisocaprotate (2-ketoisohexanoic acid, Nacalai Tesque) and 10 mM mono-
methyl succinate (methylsuccinic acid sodium salt, Sigma-Aldrich)-stimulated 
insulin secretion assays were performed in Tet-TBP-2 INS-1 cells.
Insulin secretion assay using primary mouse pancreatic islet. Insulin release 
from intact islets was monitored using batch incubation methods50. Isolated pan-
creatic islets were precultured at 37 °C for 30 min with gentle swinging (50 times 
per min) in KRBB containing 129.4 mM NaCl, 3.7 mM KCl, 2.7 mM CaCl2, 1.3 mM 
KH2PO4, 1.3 mM MgSO4, 24.8 mM NaHCO3 (equilibrated with 5% CO2, 95% O2, 
pH 7.4), and 0.2 % (vol/vol) bovine serum albumin (fraction V) with 2.8 mM 
glucose. Next, the pancreatic islets were incubated for 30 min in KRBB buffer with 
glucose 2.8 or 16.7 mM to determine insulin secretion levels. At the end of the 
incubation period, islets were pelleted by centrifugation, and aliquots of the  
buffer were sampled. The amount of immunoreactive insulin was determined  
by radioimmunoassay, using rat insulin as standard.
ATP contents assay. INS-1 cells (2.0 × 105 cells per 24-well plate) or isolated 
pancreatic islets were precultured in KRBB buffer with 2.8 mM glucose for 2 h or 
30 min, and were batch incubated for 10 or 30 min in KRBB with 2.8 or 16.7 mM 
glucose, respectively. After immediate addition of HClO4, cells were sonicated in 
ice-cold water for 10 min, and centrifuged. Part of the supernatant fraction was 
mixed with HEPES and Na2CO3 and the ATP content in the cells was determined 
by luminometer as previously described50.
Intracellular Ca2 +  assay. INS-1 cells were precultured for 2 h in KRBB with 
2.8 mM glucose and then cells were loaded with 5 µM Fura-PE3 AM in KRBB 
containing 2.8 mM glucose and 0.2% bovine serum albumin at 37 °C for 20 min. 
Intracellular Ca2 +  concentration was measured by the ratio of emission fluores-
cence of 510 nm by excitation at 340 and 380 nm as previously described50.
Measurement of mitochondrial membrane potentials. Briefly, INS-1 cells were 
preincubated in KRBB with 3 and 20 mM glucose or in cultured medium for 24 h, 
and the cells were resuspended in 0.5 ml of ice-cold PBS, then cultured with 10 nM 
jc-1 (Sigma-Aldrich, J-4519) for 15 min in 5% CO2 at 37 °C with or without 5 µM 
cccp, a protonophore that completely dissipated ∆ψ, and was analysed by flow 
cytometry (FACSCanto II, BD Bioscience) or fluorescence microscopy (Biozero,  
Keyence). The greater the mitochondrial membrane potential, the more jc-1  
aggregates form that have a red fluorescent emission signal, as opposed to the jc-1 
monomer that fluorescences green. Data acquisition and analysis were performed 
using Cell Quest Software.
Luciferase reporter assays. INS-1 cells were transiently transfected with pGL4.10 
luc2 vectors containing UCP-2 -86 enhancer region (5′-GGCTCCGCCTCGT 
CACGCCACGCCCCGACCACGCCCTCTAGA-3′) or pGL4.10 luc2 vectors, with 
the pCMV-PGC-1α, pCMV-Tag2A-TBP-2 and FLAG-HA-p160 MBP plasmids. 
FLAG-HA-p160 MBP was kindly provided by Dr Shunsuke Ishii. As a control, the 
total amount of vectors for transfection was adjusted by the amount of the pCMV-
Tag2A vector. After 18 h of transfection, luciferase activity was quantified using the 
luciferase assay system (Promega). pRL-TK (Promega) was used to monitor Renilla 
luciferase gene expression as a control for the efficiency of transfection.
Cell culture of primary MEFs. Primary MEFs were derived from 13.5-day-old 
embryos from TBP-2 + / −  mice, and then the MEFs were genotyped to obtain 
TBP-2 − / −  and TBP-2 + / +  MEFs. Cells were maintained in DMEM with 10% 
fetal calf serum, 1% penicillin and 0.5% l-glutamine. TBP-2 mRNA expression was 
confirmed by semiquantitative RT–PCR analysis. Primer sequences are listed in 
Supplementary Table S4.
Quantitative (semiquantitative) RT–PCR analysis. Total RNA was extracted from   
INS-1 cells or handpicked freshly isolated islets using TRIzol reagent (Invitrogen). 
Reverse transcription was performed with SuperScript III (Invitrogen) or Prime-
Script RT (TAKARA). Real-time RT–PCR was performed using SYBR Premix Ex 
Tag II(TAKARA). The internal control used was β-actin. PCR analyses were carried 
out using the oligonucleotide primers listed in Supplementary Table S4.
Chromatin immunoprecipitation. Chromatin was prepared from Tet-TBP-2 INS-
1 cells treated with or without doxycycline. Briefly, 5 × 106 cells were crosslinked 
with 1% formaldehyde for 10 min, followed by the addition of glycine at 125 mM. 
Chromatin was sheared by enzymes (CHIP IT Express Kit, Active Motif). Chro-
matin was immunoprecipitated with 2 µg anti-RNA polymerase II (Active Motif), 
control-mouse immunoglobulin G (Active Motif) or anti-PGC-1α antibodies 
(Santa Cruz). GATCTGAGACAGGGAGACTCTAGG and GGAGAATACACA 
GGAGAACACAGG primers were used to amplify the UCP-2 SP1, SRE, E-boxes 
region. Rat β-actin enhancer primers (Active Motif) were used as control. PCR was 
carried out with one cycle at 95 °C for 2 min; 36 cycles at 94 °C for 10 s, 60 °C for 
30 s, 68 °C for 1 min; and one cycle at 68 °C for 5 min.
Co-immunoprecipitation. To investigate interactions between TBP-2 and 
Mybbp1a in vivo, Myc-TBP-2 and FLAG-HA-Mybbp1a or pCMV-tag3B and 
pCMV-tag2A (as control) were co-expressed in HEK293 cells. Cells were lysed 
in lysis buffer (CellLytic M Cell Lysis Reagent, Sigma-Aldrich), and insoluble 
materials were precipitated by centrifugation at 15,000 × g for 15 min. The resulting 
supernatants were incubated with anti-Myc agarose beads (MBL), and bound ma-
terial was eluted with Myc-peptide (500 µg ml − 1, MBL). Protein–protein interaction 
was assessed by immunoblotting using anti-FLAG antibody (Sigma-Aldrich) or 
anti-Myc antibody (Sigma-Aldrich).
Statistical method. Results were expressed as the mean ± s.d. Statistical com-
parisons were made using Student’s t-test. A statistically significant difference was 
defined as *P < 0.05, **P < 0.01, ***P < 0.001. 
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